Literature DB >> 10802380

Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.

M S Khil1, A Kolozsvary, M Apple, J H Kim.   

Abstract

PURPOSE: Radiosurgery refers to the delivery of high, single focused beams of ionizing radiation to defined intracranial lesions. 1,3 Bis[2-chloroethyl]-1-nitrosourea (BCNU) and cis-diammine-1, 1-cyclobutane-dicarboxylate platinum (II) (carboplatin) are commonly used cytotoxic agents for the treatment of malignant gliomas of the brain. Drug therapies have exhibited a modest enhanced cell killing when combined with radiation in experimental animal tumor systems. The purpose of the present study was to investigate the role of cytotoxic drugs, such as BCNU and carboplatin, in combination with a single high dose of radiosurgery on the tumor control rates of 9L tumors in the rat brain. METHODS AND MATERIALS: Combined radiosurgery (25 Gy single dose) and/or chemotherapy (a single dose of BCNU, 7 mg/kg, i.p. 1.5 or 16 h prior to or 16 h after irradiation or a single dose of carboplatin, 30 mg/kg, administered either 1 h or 4 h prior to irradiation) was delivered 12 days after stereotactic tumor implantation. For dose escalation study, 4-10 mg/kg of BCNU was used.
RESULTS: The radiation alone group showed a dose-dependent survival. A single dose of 25 Gy to the control group resulted in an increase of the median survival time from 20 days to 42 days, but all animals died of the tumor in 50 days. A significant prolongation of the median survival time of animals was more than 100 days, resulting in animal cures of 50% or more when combined with radiosurgery (25 Gy) and BCNU (7 mg/kg). BCNU alone did not prolong the median survival time of the animal with the 9L brain tumor. In contrast, there was no survival improvement when the animals were treated with combined radiosurgery and carboplatin. None of the long-term surviving animals showed any significant brain tissue damage as evaluated by histopathology and clinical observations.
CONCLUSION: The data clearly suggest that the combined modalities of radiosurgery and concomitant BCNU represent an effective therapeutic regimen in the treatment of radioresistant human malignant gliomas of the brain. This study represents the first experimental report of the effectiveness of combined chemotherapy and radiosurgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10802380     DOI: 10.1016/s0360-3016(00)00428-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Human glioblastoma biopsy spheroids xenografted into the nude rat brain show growth inhibition after stereotactic radiosurgery.

Authors:  Frits Thorsen; Per Øyvind Enger; Jian Wang; Rolf Bjerkvig; Paal-Henning Pedersen
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

2.  Neuroinflammation After Stereotactic Radiosurgery-Induced Brain Tumor Disintegration Is Linked to Persistent Cognitive Decline in a Mouse Model of Metastatic Disease.

Authors:  Chengyan Chu; Catherine M Davis; Xiaoyan Lan; Robert D Hienz; Anna Jablonska; Aline M Thomas; Esteban Velarde; Shen Li; Miroslaw Janowski; Mihoko Kai; Piotr Walczak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-26       Impact factor: 7.038

3.  The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.

Authors:  Liping Yang; Jingxiang Zhao; Guihong Zhou; Yunfang Wang; Lusi Li; Hongfeng Yuan; Xue Nan; Lidong Guan; Xuetao Pei
Journal:  Neural Regen Res       Date:  2012-06-25       Impact factor: 5.135

4.  Gamma knife surgery as monotherapy with clinically relevant doses prolongs survival in a human GBM xenograft model.

Authors:  Bente Sandvei Skeie; Jian Wang; Ernest Dodoo; Jan Ingeman Heggdal; Janne Grønli; Linda Sleire; Sidsel Bragstad; Jeremy C Ganz; Martha Chekenya; Sverre Mørk; Paal-Henning Pedersen; Per Øyvind Enger
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.